BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36926246)

  • 1. Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment.
    Tsai JW; Choi JJ; Ouaalam H; Murillo EA; Yeo KK; Vogelzang J; Sousa C; Woods JK; Ligon KL; Warfield SK; Bandopadhayay P; Cooney TM
    Neurooncol Adv; 2023; 5(1):vdac182. PubMed ID: 36926246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
    Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
    J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma.
    Leclair NK; Lambert W; Roche K; Gillan E; Gell JJ; Lau CC; Wrubel G; Knopf J; Amin S; Anderson M; Martin JE; Bookland MJ; Hersh DS
    Neurosurg Focus; 2022 Dec; 53(6):E15. PubMed ID: 36455272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
    van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
    BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabrafenib plus Trametinib: A breakthrough in pediatric low-grade glioma therapy.
    Dar MS; Shahid N; Waqas A; Baig YA; Khan AW
    Health Sci Rep; 2024 Jan; 7(1):e1841. PubMed ID: 38274133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.
    Nobre L; Zapotocky M; Ramaswamy V; Ryall S; Bennett J; Alderete D; Balaguer Guill J; Baroni L; Bartels U; Bavle A; Bornhorst M; Boue DR; Canete A; Chintagumpala M; Coven SL; Cruz O; Dahiya S; Dirks P; Dunkel IJ; Eisenstat D; Faure Conter C; Finch E; Finlay JL; Frappaz D; Garre ML; Gauvain K; Bechensteen AG; Hansford JR; Harting I; Hauser P; Hazrati LN; Huang A; Injac SG; Iurilli V; Karajannis M; Kaur G; Kyncl M; Krskova L; Laperriere N; Larouche V; Lassaletta A; Leary S; Lin F; Mascelli S; McKeown T; Milde T; Morales La Madrid A; Morana G; Morse H; Mushtaq N; Osorio DS; Packer R; Pavelka Z; Quiroga-Cantero E; Rutka J; Sabel M; Salgado D; Solano P; Sterba J; Su J; Sumerauer D; Taylor MD; Toledano H; Tsang DS; Valente Fernandes M; van Landeghem F; van Tilburg CM; Wilson B; Witt O; Zamecnik J; Bouffet E; Hawkins C; Tabori U
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Targeted therapies with BRAF inhibitors for pediatric low- and high-grade gliomas with BRAFv600e mutation. Prof. Dr. Juan P. Garrahan Hospital experience].
    Warriner E; Fernández Ponce N; Freytes C; Sampor C; Oller A; Rugilo C; Lubieniecki F; Vazquez V; Alderete D; Baroni LV
    Medicina (B Aires); 2021; 81(5):791-799. PubMed ID: 34633954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
    Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
    J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
    Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
    Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
    Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
    J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.
    Tan JY; Wijesinghe IVS; Alfarizal Kamarudin MN; Parhar I
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33557011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characteristics of pediatric low-grade glioma complicated with ventriculo-peritoneal shunt related ascites.
    Solano-Páez P; Fonseca A; Baroni LV; Amayiri N; Somarriba MP; Freytes C; Quiroga E; Rivero M; Márquez J; Lassaletta Á; Bouffet E
    J Neurooncol; 2022 Mar; 157(1):147-156. PubMed ID: 35122583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
    Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
    J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition.
    O'Hare P; Cooney T; de Blank P; Gutmann DH; Kieran M; Milde T; Fangusaro J; Fisher M; Avula S; Packer R; Fukuoka K; Mankad K; Mueller S; Waanders AJ; Opocher E; Bouffet E; Raabe E; Werle NE; Azizi AA; Robison NJ; Hernáiz Driever P; Russo M; Schouten N; van Tilburg CM; Sehested A; Grill J; Bandopadhayay P; Kilday JP; Witt O; Ashley DM; Ertl-Wagner BB; Tabori U; Hargrave DR
    Neuro Oncol; 2024 May; ():. PubMed ID: 38743009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Pediatric Low-Grade Gliomas.
    Sait SF; Giantini-Larsen AM; Tringale KR; Souweidane MM; Karajannis MA
    Curr Neurol Neurosci Rep; 2023 Apr; 23(4):185-199. PubMed ID: 36881254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric-type low-grade gliomas in adolescents and young adults-challenges and emerging paradigms.
    Bennett J; Yeo KK; Tabori U; Hawkins C; Lim-Fat MJ
    Childs Nerv Syst; 2024 May; ():. PubMed ID: 38761264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upfront treatment with mTOR inhibitor everolimus in pediatric low-grade gliomas: A single-center experience.
    Cacchione A; Lodi M; Carai A; Miele E; Tartaglia M; Megaro G; Del Baldo G; Alessi I; Colafati GS; Carboni A; Boccuto L; Diomedi Camassei F; Catanzaro G; Po A; Ferretti E; Pedace L; Pizzi S; Folgiero V; Pezzullo M; Corsetti T; Secco DE; Cefalo MG; Locatelli F; Mastronuzzi A
    Int J Cancer; 2021 May; 148(10):2522-2534. PubMed ID: 33320972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
    Haas-Kogan DA; Aboian MS; Minturn JE; Leary SES; Abdelbaki MS; Goldman S; Elster JD; Kraya A; Lueder MR; Ramakrishnan D; von Reppert M; Liu KX; Rokita JL; Resnick AC; Solomon DA; Phillips JJ; Prados M; Molinaro AM; Waszak SM; Mueller S
    J Clin Oncol; 2024 Feb; 42(4):441-451. PubMed ID: 37978951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
    Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
    Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Inoperable Supra-Sellar Low-Grade Glioma With BRAF Mutation in Young Children.
    Howden K; Chapman S; Serletis D; Kazina C; Rafay MF; Faury D; Hazrati LN; Jabado N; Vanan MI
    Cureus; 2021 Nov; 13(11):e19400. PubMed ID: 34926002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.